Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "LAR1:uu ;pers:(Larsson Rolf);srt2:(2005-2009);pers:(Isaksson Anders);pers:(Dhar Sumeer);conttype:(refereed)"

Sökning: LAR1:uu > Larsson Rolf > (2005-2009) > Isaksson Anders > Dhar Sumeer > Refereegranskat

  • Resultat 1-3 av 3
Sortera/gruppera träfflistan
  • Fryknäs, Mårten, et al. (författare)
  • Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model
  • 2006
  • Ingår i: Journal of Biomolecular Screening. - 1087-0571. ; 11:5, s. 457-468
  • Tidskriftsartikel (refereegranskat)abstract
    • The squamous cell carcinoma HeLa cell line and an epithelial cell line hTERT-RPE with a nonmalignant phenotype were interrogated for HeLa cell selectivity in response to 1267 annotated compounds representing 56 pharmacological classes. Selective cytotoxic activity was observed for 14 of these compounds dominated by cyclic adenosine monophosphate (cAMP) selective phosphodiesterase (PDE) inhibitors, which tended to span a representation of the chemical descriptor space of the library. The PDE inhibitors induced delayed cell death with features compatible with classical apoptosis. The PDE inhibitors were largely inactive when tested against a cell line panel consisting of hematological and nonsquamous epithelial phenotypes. In a genome-wide DNA microarray analysis, PDE3A and PDE2A were found to be significantly increased in HeLa cells compared to the other cell lines. The pathway analysis software PathwayAssist was subsequently used to extract a list of proteins and small molecules retrieved from Medline abstracts associated with the hit compounds. The resulting list consisted of major parts of the cAMP-protein kinase A pathway linking to ERK, P38, and AKT. This molecular network may provide a basis for further exploitation of novel candidate targets for the treatment of squamous cell carcinoma.
  • Fryknäs, Mårten, et al. (författare)
  • STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines
  • 2007
  • Ingår i: International Journal of Cancer. - 0020-7136. ; 120:1, s. 189-195
  • Tidskriftsartikel (refereegranskat)abstract
    • The myeloma cell line RPMI 8226/S and its doxorubicin resistant subline 8226/Dox40 were used as models to explore the potential importance of the STAT1 signaling pathway in drug and radiation resistance. The 40-fold doxorubicin resistant subline 8226/Dox40 was found to be crossresistant to single doses of 4 and 8 Gy of radiation. A genome-wide mRNA expression study comparing the 8226/Dox40 cell line to its parental line was performed to identify the underlying molecular mechanisms. Seventeen of the top 50 overexpressed genes have previously been implicated in the STAT1 signaling pathway. STAT1 was over expressed both at the mRNA and protein level. Moreover, analyses of nuclear extracts showed higher abundance of phosphorylated STAT1 (Tyr 701) in the resistant subline. Preexposure of the crossresistant cells to the STAT1 inhibiting drug fludarabine reduced expression of overexpressed genes and enhanced the effects of both doxorubicin and radiation. These results show that resistance to doxorubicin and radiation is associated with increased STAT1 signaling and can be modulated by fludarabine. The data support further development of therapies combining fludarabine and radiation.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-3 av 3
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy